Precision medicine for focal segmental glomerulosclerosis

Area of Science:

• Nephrology
• Genetics
• Biomarker Discovery

Background:

• Focal segmental glomerulosclerosis (FSGS) is a leading cause of nephrotic syndrome globally in both children and adults.
• Current histopathological classification of FSGS presents challenges in differentiating pathogenesis, disease progression, and treatment responses.
• Advances in next-generation sequencing and biological techniques are reshaping the understanding of FSGS.

Purpose of the Study:

• To review the application of genetic testing in FSGS patients.
• To explore the clinical significance of genetic identification in FSGS.
• To introduce novel biomarkers for early FSGS diagnosis and targeted therapy development.

Main Methods:

• Review of current literature on genetic testing in FSGS.
• Analysis of the clinical utility of genetic identification.
• Discussion of emerging biomarkers for FSGS.

Main Results:

• Genetic testing provides a deeper understanding of FSGS heterogeneity.
• Biomarkers show potential for earlier and more accurate FSGS diagnosis.
• Identification of genetic factors and biomarkers facilitates personalized medicine approaches.

Conclusions:

• Genetic testing is crucial for understanding FSGS pathogenesis and guiding treatment.
• Novel biomarkers are essential for early diagnosis and the development of targeted therapies.
• Advancing precision medicine in FSGS through genetic and biomarker insights promises more effective and safer treatments.